Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis
AuthorShubitz, Lisa F.
Robb, Edward J.
Powell, Daniel A.
Bowen, Richard A.
Porter, Stephanie M.
Orbach, Marc J.
Frelinger, Jeffrey A.
Galgiani, John N.
AffiliationValley Fever Center for Excellence, The University of Arizona
Department of Immunobiology, The University of Arizona
School of Plant Sciences, The University of Arizona
Department of Medicine, The University of Arizona
MetadataShow full item record
CitationShubitz, L. F., Robb, E. J., Powell, D. A., Bowen, R. A., Bosco-Lauth, A., Hartwig, A., Porter, S. M., Trinh, H., Moale, H., Bielefeldt-Ohmann, H., Hoskinson, J., Orbach, M. J., Frelinger, J. A., & Galgiani, J. N. (2021). Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine.
Rights© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractCoccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Δcps1, was tested for tolerability and efficacy to prevent pulmonary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but disease scores were not significantly different from unvaccinated (P = 0.675). Δcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Δcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans.
NoteOpen access article
VersionFinal published version
Except where otherwise noted, this item's license is described as © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).